Immune stimulatory effect of anti-EpCAM immunotoxin – improved overall survival of metastatic colorectal cancer patients

References

• Gnjatic S, Bronte V, Brunet LR, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017;5:44.
   PubMed Web of Science ®Google Scholar
• Kamta J, Chaar M, Ande A, et al. Advancing cancer therapy with present and emerging immuno-oncology approaches. Front Oncol. 2017;7:64.
   PubMed Web of Science ®Google Scholar
• Dempke WCM, Fenchel K, Uciechowski P, et al. Second- and third-generation drugs for immuno-oncology treatment—the more the better? Eur J Cancer. 2017;74:55–72.
   PubMed Web of Science ®Google Scholar
• Andersson Y, Juell S, Fodstad O. Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin. Int J Cancer. 2004;112:475–483.
   PubMed Web of Science ®Google Scholar
• Andersson Y, Le H, Juell S, et al. AMP-activated protein kinase protects against anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin-induced MA11 breast cancer cell death. Mol Cancer Ther. 2006;5:1050–1059.
   PubMed Web of Science ®Google Scholar
• Risberg K, Fodstad O, Andersson Y. Immunotoxins: a promising treatment modality for metastatic melanoma? Ochsner J. 2010;10:193–199.
   PubMedGoogle Scholar
• Andersson Y, Engebraaten O, Juell S, et al. Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. Br J Cancer. 2015;113:1548–1555.
   PubMed Web of Science ®Google Scholar
• Andersson Y, Engebraaten O, Fodstad O. Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. Br J Cancer. 2009;101:1307–1315.
   PubMed Web of Science ®Google Scholar
• Subklewe M, Sebelin-Wulf K, Beier C, et al. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol. 2007;68:147–155.
   PubMed Web of Science ®Google Scholar
• Risberg K, Fodstad O, Andersson Y. The melanoma specific 9.2.27PE immunotoxin efficiently kills melanoma cells in vitro. Int J Cancer. 2009;125:23–33.
   PubMed Web of Science ®Google Scholar
• Spranger S, Javorovic M, Bürdek M, et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol. 2010;185:738–747.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3:e955691.
   PubMed Web of Science ®Google Scholar
• Grothey A, Cutsem EV, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–312.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–1919.
   PubMed Web of Science ®Google Scholar
• Andersen SE, Andersen IB, Jensen BV, et al. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. Acta Oncol. 2019;58:1149–1157.
   PubMed Web of Science ®Google Scholar
• Zhao L, Yang Y, Li W, et al. Pseudoprogression: an indicator for cure in combined immunotherapy? Immunotherapy. 2019;11:1087–1093.
   PubMed Web of Science ®Google Scholar
• Beer L, Hochmair M, Haug AR, et al. Comparison of RECIST, iRECIST, and PERCIST for the evaluation of response to PD-1/PD-L1 blockade therapy in patients with non-small cell lung cancer. Clin Nucl Med. 2019;44:535–543.
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6:559–565.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
   PubMed Web of Science ®Google Scholar
• Garg AD, De Ruysscher D, Agostinis P. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: a large-scale meta-analysis. Oncoimmunology. 2016;5:e1069938.
   PubMed Web of Science ®Google Scholar
• Lohmueller J, Finn OJ. Current modalities in cancer immunotherapy: immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther. 2017;178:31–47.
   PubMed Web of Science ®Google Scholar
• Kuusk T, Albiges L, Escudier B, et al. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis. 2017;20:205–215.
   PubMed Web of Science ®Google Scholar
• Esposito A, Criscitiello C, Curigliano G. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. Curr Opin Oncol. 2015;27:445–451.
   PubMed Web of Science ®Google Scholar